)
)
AlloVir Investor Relations Material
Latest events
EGM 2025
AlloVir
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from AlloVir Inc
Access all reports
AlloVir, Inc. is a clinical-stage biotechnology company focused on developing allogeneic, virus-specific T cell (VST) therapies. Its proprietary platform enables the creation of off-the-shelf VSTs designed to prevent and treat severe viral diseases, particularly in patients with compromised immune systems. The company's lead product candidate, posoleucel, targets multiple viruses, including adenovirus, cytomegalovirus, and Epstein-Barr virus. AlloVir's pipeline also includes therapies in development for respiratory and other viral infections. The company is headquartered in Waltham, Massachusetts, and its shares are listed on the NASDAQ.
Latest articles
)
Adobe: Equipping the Architects of Digital Expression
The story of how Adobe grew from a small garage upstart to one of the largest and most dominant software companies in the world.
21 Mar 2025
)
James Quincey: Coca-Cola Chairman and CEO
James Quincey has dedicated nearly three decades to The Coca-Cola Company, rising through the ranks to become CEO and Chairman of the company.
11 Mar 2025
)
PepsiCo: From Pepsi and Gatorade to Doritos and Lay's
PepsiCo has grown from a soda company into a global leader in food and beverages, with a portfolio of over 200 brands, including Pepsi, Lay's, and Gatorade.
11 Mar 2025
Ticker symbol
ALVR
Country
🇺🇸 United States